Related references
Note: Only part of the references are listed.Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl)quinoxalines as PI3Kα inhibitors
Peng Wu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2011)
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
M. Christine Hollander et al.
NATURE REVIEWS CANCER (2011)
PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
P. Wu et al.
CURRENT MEDICINAL CHEMISTRY (2010)
The emerging mechanisms of isoform-specific PI3K signalling
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Steven D. Knight et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Kiyotaka Kawauchi et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Peng Wu et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Targeting phosphoinositide 3-kinase - Moving towards therapy
Romina Marone et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2008)
Cancer-specific mutations in phosphatidylinositol 3-kinase
Peter K. Vogt et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors
Masahiko Hayakawa et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Share Paper
